John Parkinson

The fast-moving Omicron variant demonstrates a high transmissibility, but not as significant a hospitalization rate or mortality.

A phase 3 trial shows one dose is 91.7 % effective against severe disease.

Stigma, and a lack of communication and awareness all inhibit HIV PrEP uptake, but digital health and new forms of PrEP are aiming to increase users.

This is the first pill to treat COVID-19 in trying to prevent progression to severe disease and possible hospitalization.

The administration is going to buy 500 million at-home rapid COVID-19 tests, and make them available to Americans. They also plan to use federal resources to provide pop-up clinics and get more pharmacists involved in vaccinations.

The therapy becomes the first injectable approved in the United States for this indication.

The proposed funding will include a number of measures of spending towards HIV and prevention, including community centers for PrEP education.

The website, LearnAntibiotics.com, is a supplemental tool offering guides, practice exams, and other resources to help students, residents, or practicing professionals with infectious diseases pharmacotherapy.

The company believes the pill should work against the Omicron variant.

Data indicate that a third dose of the Pfizer-BioNTech vaccine, BNT162b2, increases the neutralizing antibody titers by 25-fold compared to 2 doses against the Omicron variant.

The strategies address booster doses, travel, and rapid response.

The first Omicron COVID-19 case was discovered in California. The patient, who traveled from South Africa, has since recovered.

As there is a lot of information regarding the Omicron variant, here is our latest slideshow to offer some insights on it.

Moderna and Pfizer's CEOs voice doubt on the current vaccines’ efficacy with the new variant, but are developing prophylaxis vaccines and treatment strategies to curtail the new strain.

The strain identified as B.1.1.529 is causing some travel restrictions from some African countries, and medical science is rushing to understand its potential impact on the global stage.

HIV Stakeholders weigh on the future of PrEP.

The federal agency's decision makes this the first CMV treatment for this patient population.

This infection has the ability to remain undetected and the potential to spread very quickly in long-term care facilities and hospitals.

As providers were challenged to care for patients with severe COVID-19 In the first year of the pandemic, antibiotic usage increased. Listen to clinicians talk about this specific challenge and how prescribing practices evolved over time.

From its origins as a serendipitous discovery to being successfully prescribed for nearly a century, antibiotics remain a foundation of medicine. However it has major ongoing challenges including the rise of superbugs and the development of antimicrobial resistance (AMR). There are some prospective strategies to combat AMR on the horizon.

Providers and key stakeholders weigh in on this significant topic.

CEO Christopher Burns spoke about their investigational therapy pipeline, the long view perspective for the company, and how the federal government’s use of the nomenclature innovation might actually hinder incremental improvements in antibiotic development.

This agreement with the Medicines Patient Pool (MPP) would allow licensing of the company’s antiviral treatment candidate, PF-07321332, internationally to numerous countries.

How 1 provider is training medical peers to offer PrEP education and prescribe it.

Fenway Health’s Pride in Our Health podcast is an example of new voices being heard, and an alternative means of getting health information to the general public.

Clinical care is evolving in this area and shows promise in the various modalities and therapies that are going through clinical trials.

During the C Diff Foundation's Annual conference, providers and stakeholders offered insights on the latest investigational therapies and modalities as they advance through clinical trials.

Results on this investigational antibiotic in its phase 2A study were presented at the C Diff. Conference today.

At the C Diff Foundation Conference, promising investigational modalities and therapies, as well as better treatment approaches are all being discussed in hopes of some real inroads being made in this field in the near future.

Although no longer indicated as a first-line therapy, metronidazole still has therapeutic benefits and can serve patients in certain settings and circumstances.